1.. Introduction {#s1}
================

Invasive pneumococcal disease (IPD) caused by *Streptococcus pneumoniae* is a major cause of morbidity and mortality worldwide, especially in young children and elderly people; its most severe manifestations include bacteremia, septicemia, bacteremic pneumonia, and meningitis \[[@B1],[@B2]\]. A previous study conducted in 1999--2003 in Saudi Arabia has estimated an average annual IPD incidence of 17.4/100,000 children younger than 5 years of age, a case fatality rate of 12.2%, and an almost fourfold higher incidence of IPD in the 1st year of life compared with the next 4 years \[[@B3]\]. That study may underestimate the true IPD burden in Saudi Arabia since only microbiologically confirmed IPD cases (meningitis or bacteremia) were included in the analyses \[[@B3]\]. Additionally, as the study focused only on hospitalized children, outpatient bacteremia was not assessed and blood cultures from pneumonia were frequently not performed \[[@B3]\].

Currently, more than 90 pneumococcal serotypes have been identified based on differences in capsular polysaccharides. The serotype distribution varies somewhat between different geographical regions, especially regarding the relative prominence of serotypes 1 and 5 \[[@B4],[@B5]\]. In a study conducted in 2000--2004 on 350 isolates collected from children in different regions of Saudi Arabia, the most common invasive *S. pneumoniae* serotype was 14, followed by serotypes 23F, 6B, and 19F. These serotypes were shown to account for 80% of the invasive pneumococcal isolates resistant to widely used antibiotics (penicillin, erythromycin, and cefotaxime); in Saudi Arabia, different antibiotics are prescribed against these pathogens as there are no national guidelines \[[@B6]\].

Other studies conducted in Saudi Arabia have shown a high and increasing prevalence of multidrug-resistant *S. pneumoniae* isolates \[[@B6]--[@B14]\]. The emergence of antimicrobial resistance among pneumococcal isolates is a major health problem in many other countries and is mainly due to the extensive and inappropriate use of antibiotics \[[@B15]\].

Since certain serotypes occur with different frequencies due to outbreaks, temporal variability in serotype distribution can be observed. The existing data need to be updated and the relative value of expanded serotype conjugate vaccines needs to be understood. Moreover, the true IPD incidence rate in Saudi Arabia remains unclear, as does the geographical representativeness of previous studies. The current clinical study assesses the incidence per health area (except Riyadh and Jeddah) of IPD in Saudi Arabian children younger than 5 years of age, along with the distribution of pneumococcal serotypes and antibiotic susceptibility of *S. pneumoniae* isolates, in both inpatient and outpatient populations that had not yet benefited from the introduction of pneumococcal conjugate vaccination. Additionally, this study attempted to provide information on other bacterial pathogens causing invasive disease in Saudi Arabian children, such as *Haemophilus influenzae* and *Neisseria meningitidis* and to describe antimicrobial drug resistance patterns of these pathogens in Saudi Arabian children suspected of having IPD.

2.. Materials and methods {#s2}
=========================

2.1.. Study design and participants {#s2.1}
-----------------------------------

This multicenter, prospective, national, clinical surveillance study was conducted in 12 hospitals located in seven health areas (Al Gassim, Al Baha, Al Jouf, Al Madeenah, Al Qateef, Riyadh City, and Jeddah City), to represent the epidemiology and disease burden across Saudi Arabia. The selected study hospitals from Riyadh and Jeddah do not accurately represent the catchment area for these two cities because of other private and public healthcare centers not included in this study; for this reason the two areas were excluded from the incidence calculation. The recruitment period was longer than 1 year to take seasonal variations into account (June 2007--January 2009). The study was conducted according to Good Clinical Practice, the Declaration of Helsinki, and the local rules and regulations of the country. The study protocol and the consent form were reviewed and approved by the Ministry of Health or the National Independent Ethics Committee. Before enrollment, informed consent was obtained from the parents/guardians of each study participant.

This study included children younger than 5 years of age suspected of having IPD, who were residents of the study areas and were brought to one of the study hospitals. Suspected IPD cases were identified by the local physicians according to their individual clinical judgment. IPD was suspected if at least one of the following pulmonary symptoms was present: dyspnea, chest discomfort, pleuritic pain, chest splinting, cough productive of purulent or blood-tinged sputum, tachypnea, or tachycardia. Other symptoms included fever (axillary temperature \>37.5 °C), elevated white blood cells (\>15,000), suspicion of meningitis, or systemic complains. At each study hospital, attempts were made to provide enhanced education to physicians regarding the value of blood culturing when IPD was suspected. IPD was confirmed if *S. pneumoniae* was isolated from a normally sterile site, regardless of the clinical symptoms.

Children were eligible if sterile site samples (blood, cerebrospinal fluid, pleural fluid, or synovial fluid) had been collected by the local clinician less than 24 h after the hospital visit/admission. If a child was enrolled more than once for the same *S. pneumoniae* infection, only the first episode was retained for analysis. A case was considered a new *S. pneumoniae* infection if symptoms occurred at least 21 days after the first episode with the same pathogen or if the serotype was different. As serotyping was not performed at the hospital, all children meeting the inclusion criteria were enrolled.

2.2.. Study procedures {#s2.2}
----------------------

All children younger than 5 years of age with clinical symptoms of IPD were anonymously recorded in a screening logbook. Two different logbooks were used: one for the outpatients and emergency room patients (hereafter referred to as outpatient group) and another for the hospitalized patients who had at least one overnight stay in hospital before diagnosis (inpatient group).

For sterile site samples collected less than 24 h after hospital visit/admission, parents/guardians were asked to sign the informed consent, and inclusion criteria were checked to enroll the children in the study. Clinical and demographic characteristics, including risk factors (chronic pulmonary disease or asthma; immunosuppression or immunodeficiency; HIV positive or AIDS; malignancy, leukemia, or Hodgkin's disease; splenectomy or asplenia; sickle cell anemia; renal dysfunction; chronic cardiovascular disease or failure; cerebrospinal fluid leak; malnutrition; burns; or other), pneumococcal conjugate vaccination history, general symptoms, and antibiotic pretreatment were recorded in a case report form (CRF) for each enrolled child.

Samples were cultured and bacterial isolates identified at local laboratories. These bacterial isolates were shipped together with the CRF to the central laboratory at King Saud University for re-identification, serotyping, and antibiotic susceptibility testing. Samples were preferably collected before antibiotic administration, but if the child had received antibiotic at any point before taking the sterile site sample, this was stated in the CRF together with the type of antibiotic taken. (The laboratory procedures are available in the [Supplementary material](#APP1){ref-type="app"}.)

2.3.. Statistical analysis {#s2.3}
--------------------------

The estimation of the expected annual incidence of IPD was based on incidences reported in hospital-based studies in Europe (20--40/100,000 children \<5 years of age) \[[@B5],[@B16]\]. Based on these estimates, a minimum of 37--75 episodes were expected in this study.

Calculations for the incidence rates of invasive disease due to *S. pneumoniae*, *H. influenzae*, or *N. meningitidis* were derived from the total number of new episodes of confirmed invasive disease caused by each pathogen, including those episodes for which no informed consent was obtained.

This was a descriptive study and no statistical comparisons were performed. Continuous variables were described with the number of nonmissing observations, mean, standard deviation, median, minimum and maximum, and number of missing observations. Categorical variables were described with frequency tables and absolute numbers and percentages for each level were given. All confidence intervals were two-sided 95% confidence intervals and were calculated from Proc StatXact. All statistical analyses were performed using SAS version 9.2.

3.. Results {#s3}
===========

3.1.. Demographic and baseline characteristics of enrolled individuals {#s3.1}
----------------------------------------------------------------------

Between June 2007 and January 2009, 1030 episodes were screened, 631 of which were recorded as suspected IPD. Six hundred and twenty-three episodes in 622 children were analyzed: 621 children who experienced a single infection and one child who had two infections.

Forty-five episodes (7.2%) were reported in infants \<1 month of age, 290 episodes (46.5%) in infants aged 1 month--1 year, and the remaining 288 episodes (46.2%) in children 1--5 years of age ([Table 1](#T1){ref-type="table"}). Of the 623 episodes, 61.8% (385/623) were reported in the inpatient group and 38.2% (238/623) in the outpatient group. The mean age of the children was 15.0 ± 14.2 months; 45.3% (282/623) of episodes occurred in girls. In this study, one child (0.2%) had received pneumococcal vaccination prior to enrollment. Baseline characteristics of the enrolled children were similar to those of the screened children.

###### 

Demographic characteristics and clinical information regarding children suspected of having IPD who were included in the study.

                                                                    Inpatients[^a^](#TFN2){ref-type="table-fn"}   Outpatients[^b^](#TFN3){ref-type="table-fn"}   Total
  ----------------------------------------------------------------- --------------------------------------------- ---------------------------------------------- -------------
  *N*[^c^](#TFN4){ref-type="table-fn"}                              385                                           238                                            623
  Age (mo) (mean ± SD)                                              15.9 ± 14.8                                   13.4 ± 12.9                                    15.0 ± 14.2
  *Age category (mo) n*[^d^](#TFN5){ref-type="table-fn"} (%)                                                                                                     
  \<1                                                               28 (7.3)                                      17 (7.1)                                       45 (7.2)
  1--11                                                             172 (44.7)                                    118 (49.6)                                     290 (46.5)
  12--59                                                            185 (48.1)                                    103 (43.3)                                     288 (46.2)
  *Gender n* (%)                                                                                                                                                 
  Male                                                              215 (55.8)                                    126 (52.9)                                     341 (54.7)
  *Pneumococcal vaccination n* (%)                                                                                                                               
  Yes                                                               1 (0.3)                                       0 (0.0)                                        1 (0.2)
  *Antibiotic pretreatment n* (%)                                                                                                                                
  Yes                                                               40 (10.4)                                     64 (26.9)                                      104 (16.7)
  Unknown                                                           16 (4.2)                                      25 (10.5)                                      41 (6.6)
  *Antibiotic taken in hospital prior to sample collection n* (%)                                                                                                
  Yes                                                               2 (0.5)                                       8 (3.4)                                        10 (1.6)
  *Hospitalization after diagnosis*                                                                                                                              
  *n* (%)                                                           385 (100)                                     236 (99.2)                                     621 (99.7)
  Duration (d) (mean ± SD)                                          6.0 ± 7.4                                     7.6 ± 8.1                                      6.6 ± 7.7

IPD = invasive pneumococcal disease; SD = standard deviation.

Hospitalized patients with at least one overnight stay in hospital before diagnosis.

Outpatients and patients brought to emergency room.

Total number of episodes.

Number (percentage) of episodes in the specified category.

3.2.. Clinical management {#s3.2}
-------------------------

Pretreatment with antibiotics within the past 48 h before the hospital visit/admission was reported in 104/623 (16.7%) episodes ([Table 1](#T1){ref-type="table"}). Overall, 621/623 (99.7%) episodes were followed by hospitalization after diagnosis, and the mean duration of hospitalization was 6.6 days. The most frequent presentation leading to suspicion of IPD was pneumonia, reported in 387/623 (62.1%) episodes ([Table 2](#T2){ref-type="table"}). Pneumonia was confirmed only by using an X-ray in 97.9% (379/387) as opposed to cases confirmed by detection of pleural effusion/empyema in 2.1% (8/387) of these episodes.

###### 

Clinical presentation of children suspected of having IPD.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical presentation at the visit                Inpatients[^a^](#TFN7){ref-type="table-fn"}\   Outpatients[^b^](#TFN8){ref-type="table-fn"}\>\   Total\>\
                                                    *N*[^c^](#TFN9){ref-type="table-fn"}*=*385     *N =* 238                                         *N =* 623
  ------------------------------------ ------------ ---------------------------------------------- ------------------------------------------------- ------------
  Bacteremia without focus             Yes          99 (25.7)                                      36 (15.1)                                         135 (21.7)

  Meningitis                           Yes          29 (7.5)                                       16 (6.7)                                          45 (7.2)

  Pneumonia                            Yes          216 (56.1)                                     171 (71.8)                                        387 (62.1)

  X-ray confirmed pneumonia            Yes          212 (98.1)                                     167 (97.7)                                        379 (97.9)

                                       Missing/NA   169 (−)                                        67 (−)                                            236 (−)

  Pleural effusion/empyema             Yes          4 (1.9)                                        4 (2.3)                                           8 (2.1)

                                       Missing/NA   169 (−)                                        67 (−)                                            236 (−)

  Otitis media                         Yes          16 (4.2)                                       10 (4.2)                                          26 (4.2)

  Bronchitis                           Yes          8 (2.1)                                        0 (0.0)                                           8 (1.3)

  Epiglottitis                         No           385 (100)                                      238 (100)                                         623 (100)

  Peritonitis                          No           385 (100)                                      238 (100)                                         623 (100)

  Pericarditis                         Yes          0 (0.0)                                        2 (0.8)                                           2 (0.3)

  Cellulitis                           Yes          1 (0.3)                                        3 (1.3)                                           4 (0.6)

  Septic arthritis                     Yes          1 (0.3)                                        1 (0.4)                                           2 (0.3)

  Osteomylitis                         Yes          1 (0.3)                                        0 (0.0)                                           1 (0.2)

  Abscess (not skin)                   Yes          2 (0.5)                                        0 (0.0)                                           2 (0.3)

  Other                                Yes          43 (11.2)                                      17 (7.1)                                          60 (9.6)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------

IPD = invasive pneumococcal disease; NA = not applicable.

Hospitalized patients with at least one overnight stay in hospital before diagnosis.

Outpatients and patients brought to emergency room.

Total number of episodes.

Number (percentage) of episodes in the specified category.

Risk factors for IPD were present in 149/623 (23.9%) episodes. The most frequently reported condition was chronic pulmonary disease/asthma, present in 56/149 (37.6%) episodes, followed by chronic cardiovascular disease in 25/149 (16.8%) episodes, and sickle cell anemia in 18/149 (12.1%) episodes.

At discharge, 598/623 (96.0%) episodes had recovered. However, seven children (1.1%) died during this study; one episode (0.2%) was followed by sequelae, and two episodes (0.3%) resulted in neurological problems due to IPD.

3.3.. Identification and incidence of pathogens {#s3.3}
-----------------------------------------------

Only 50/623 (8.0%) blood samples tested positive for bacteria and were sent to the central laboratory for further testing ([Table 3](#T3){ref-type="table"}). Cerebrospinal fluid was collected for 125/623 (20.1%) episodes, out of which only eight samples (6.4%) tested positive for bacteria and were sent to the central laboratory. Two blood samples and one cerebrospinal fluid sample were lost and thus could not be further tested for antibiotic susceptibility and serotype determination. Out of the 50 episodes confirmed for invasive disease, 47 were positive for *S. pneumoniae* and three for *H. influenzae*, with no cases of co-infection. No samples were positive for *N. meningitidis*. Of the 47 episodes positive for *S. pneumoniae*, 22 were reported in infants younger than 1 year of age and 25 in children 1--5 years of age. Overall, the presence of *S. pneumoniae* was confirmed in 7.5% (47/623) of suspected IPD episodes.

###### 

Bacterial etiology determined at local and central laboratories by sterile site sample.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Laboratory                                                      Sample origin                 Characteristics    Categories   Inpatients[^a^](#TFN12){ref-type="table-fn"}\   Outpatients[^b^](#TFN13){ref-type="table-fn"}\   Total\
                                                                                                                                *N*[^c^](#TFN14){ref-type="table-fn"} = 385     *N =* 238                                        *N =* 623
  --------------------------------------------------------------- ----------------------------- ------------------ ------------ ----------------------------------------------- ------------------------------------------------ -----------
  Local hospital                                                  Blood                         Sample collected   Yes          385 (100)                                       238 (100)                                        623 (100)

  Bacterial species identified                                    *Streptoccoccus pneumoniae*   27 (7.0)           20 (8.4)     47 (7.6)                                                                                         

  *Haemophilus influenzae*                                        3 (0.8)                       0 (0.0)            3 (0.5)                                                                                                       

  Other                                                           354 (92.2)                    218 (91.6)         572 (92.0)                                                                                                    

  Missing/NA                                                      1 (--)                        0 (--)             1 (--)                                                                                                        

  Cerebro-spinal fluid                                            Sample collected              Yes                80 (20.8)    45 (18.9)                                       125 (20.1)                                       

  Bacterial species identified                                    *S. pneumoniae*               4 (5.1)            4 (8.9)      8 (6.5)                                                                                          

  Other                                                           75 (94.9)                     41 (91.1)          116 (93.5)                                                                                                    

  Missing/NA                                                      306 (--)                      193 (--)           499 (--)                                                                                                      

  Pleural fluid                                                   Sample collected              Yes                1 (0.3)      1 (0.4)                                         2 (0.3)                                          

  Bacterial species identified                                    Other                         1 (100)            1 (100)      2 (100)                                                                                          

  Missing/NA                                                      384 (--)                      237 (--)           621 (--)                                                                                                      

  Other[^c^](#TFN14){ref-type="table-fn"} normally sterile site   Sample collected              Yes                4 (1.0)      13 (5.5)                                        17 (2.7)                                         

  Bacterial species identified                                    Other                         4 (100)            13 (100)     17 (100)                                                                                         

  Missing/NA                                                      381 (--)                      225 (--)           606 (--)                                                                                                      

  Central laboratory                                              Blood                         Sample received    Yes          28 (7.3)                                        20 (8.4)                                         48 (7.7)

  Bacterial species identified                                    *S. pneumoniae*               26 (92.9)          20 (100)     46 (95.8)                                                                                        

  *H. influenzae*                                                 2 (7.1)                       0 (0.0)            2 (4.2)                                                                                                       

  Missing/NA                                                      357 (--)                      218 (--)           575 (--)                                                                                                      

  Cerebro-spinal fluid                                            Sample received               Yes                1 (0.3)      0 (0.0)                                         1 (0.2)                                          

  Bacterial species identified                                    *S. pneumoniae*               1 (100)            0 (--)       1 (100)                                                                                          

  Missing/NA                                                      384 (--)                      238 (--)           622 (--)                                                                                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA = not applicable.

Hospitalized patients with at least one overnight stay in hospital before diagnosis.

Outpatients and patients brought to emergency room.

Total number of episodes. Bacterial species except *S. pneumoniae*, *H. influenzae* and *Neisseria meningitides*.

Number (percentage) of episodes in the specified category.

Of the 48 samples tested by the central laboratory, 46 were positive for *S. pneumoniae* and were serotyped (26 in the inpatient group; 20 in the outpatient group). The most frequently isolated pneumococcal serotypes were 5 and 23F, which were each identified in 9/46 episodes (20%), followed by 6B in 8/46 episodes (17%), and 1 and 14, each in 5/46 episodes (11%) ([Table 4](#T4){ref-type="table"}). Serotype 23F was more frequently identified in the outpatient group than in the inpatient group (6/20 versus 3/26). Serotypes 1 and 5 seemed to be more frequently identified in the inpatient group (4/26 and 6/26) than in the outpatient group (1/20 and 3/20). Of note, serotype 19A was only identified in one sample (2.2%) in this study.

###### 

Serotype distribution of *Streptococcus pneumoniae* isolates causing invasive pneumococcal disease in children \<5 years of age.

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Pneumococcal serotype   Inpatients[^a^](#TFN16){ref-type="table-fn"}\   Outpatients[^b^](#TFN17){ref-type="table-fn"}\   Total\                
                          *N*[^c^](#TFN18){ref-type="table-fn"} = 26      *N* = 20                                         *N* = 46              
  ----------------------- ----------------------------------------------- ------------------------------------------------ ---------- ------ --- ------
  1                       4                                               15.4                                             1          5.0    5   10.9

  4                       1                                               3.8                                              1          5.0    2   4.3

  5                       6                                               23.1                                             3          15.0   9   19.6

  6B                      4                                               15.4                                             4          20.0   8   17.4

  9V                      0                                               0.0                                              1          5.0    1   2.2

  11A                     1                                               3.8                                              0          0.0    1   2.2

  14                      3                                               11.5                                             2          10.0   5   10.9

  15                      2                                               7.7                                              0          0.0    2   4.3

  19A                     1                                               3.8                                              0          0.0    1   2.2

  19F                     1                                               3.8                                              2          10.0   3   6.5

  23F                     3                                               11.5                                             6          30.0   9   19.6
  -----------------------------------------------------------------------------------------------------------------------------------------------------

Hospitalized patients with at least one overnight stay in hospital before diagnosis.

Outpatients and patients brought to emergency room.

Total number of episodes.

Number (percentage) of episodes in the specified category.

The point estimates for incidence of confirmed IPD cases, caused by *S. pneumoniae*, varied between 2.5/100,000 and 21.6/100,000 children \<5 years of age in the different health areas included ([Table 5](#T5){ref-type="table"}).

###### 

Incidence of confirmed invasive disease episodes by health area and pathogen for children \<5 years of age.

  Health area          Bacterial species            *n*[^a^](#TFN22){ref-type="table-fn"}   *N*[^b^](#TFN23){ref-type="table-fn"}   Incidence per 100,000 (95% CI)
  -------------------- ---------------------------- --------------------------------------- --------------------------------------- --------------------------------
  Buraidah             *Haemophilus influenzae*     2                                       49,461                                  4.04 (0.49--14.61)
                       *Streptococcus pneumoniae*   4                                       49,461                                  8.09 (2.20--20.71)
  Al Baha City         *S. pneumoniae*              4                                       18,549                                  21.56 (5.88--55.21)
  Sikaka Province      *S. pneumoniae*              1                                       17,685                                  5.65 (0.14--31.50)
  Al Madeenah City     *S. pneumoniae*              9                                       94,246                                  9.55 (4.37--18.13)
  Al Qateef Province   *S. pneumoniae*              1                                       39,613                                  2.52 (0.06--14.07)
  Riyadh City          *S. pneumoniae*              26                                      --                                      --
  Jeddah City          *H. influenzae*              1                                       --                                      --
                       *S. pneumoniae*              2                                       --                                      --

The catchment area for Riyadh City and Jeddah City were not available.

CI = confidence interval.

Number of confirmed episodes of invasive pneumococcal disease.

Population of children \<5 years of age in the given health area during 2007.

Two of the three confirmed *H. influenzae* episodes were identified in infants \<1 year of age. Both *H. influenzae* positive samples sent to the central laboratory were nontypeable (data not shown). The number of *H. influenzae* positive samples was too small to calculate incidences by region.

3.4.. Antibiotic susceptibility {#s3.4}
-------------------------------

Among the *S. pneumoniae* isolates tested for antibiotic susceptibility, 78% (36/46) were multidrug resistant ([Table 6](#T6){ref-type="table"}). The majority of isolates had low susceptibility to penicillin: 30% (14/46) showed intermediate resistance and 39% (18/46) were resistant. Additionally, 30% of isolates were resistant to chloramphenicol, while 43% showed intermediate resistance and 54% were resistant to trimethoprim--sulfamethoxazole. All isolates were sensitive to ceftriaxone.

###### 

Antibiotic susceptibility of *Streptococcus pneumoniae* isolates from children \<5 years of age.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                             Categories     Inpatients[^a^](#TFN24){ref-type="table-fn"}\   Outpatients[^b^](#TFN25){ref-type="table-fn"}\   Total\                   
                                                             *N*[^c^](#TFN26){ref-type="table-fn"} = 26      *N* = 20                                         *N* = 46                 
  ------------------------------------------- -------------- ----------------------------------------------- ------------------------------------------------ ---------- ------ ------ ------
  Antibiotics susceptibility test performed   Yes            26                                              100                                              20         100    46     100

  Multidrug resistance                        Yes            16                                              61.5                                             13         65.0   29     63.0

  No                                          10             38.5                                            7                                                35.0       17     37.0   

  Penicillin                                  Intermediate   10                                              38.5                                             4          20.0   14     30.4

  Resistant                                   10             38.5                                            8                                                40.0       18     39.1   

  Azithromycin                                Intermediate   2                                               7.7                                              0          0.0    2      4.3

  Resistant                                   10             38.5                                            6                                                30.0       16     34.8   

  Amoxicillin/clavulanate                     Intermediate   0                                               0.0                                              3          15.0   3      6.5

  Trimethoprim/sulfamethoxazole               Intermediate   9                                               34.6                                             11         55.0   20     43.5

  Resistant                                   16             61.5                                            9                                                45.0       25     54.3   

  Chloramphenicol                             Resistant      6                                               23.1                                             8          40.0   14     30.4

  Cefaclor                                    Intermediate   1                                               3.8                                              1          5.0    2      4.3

  Resistant                                   15             57.7                                            9                                                45.0       24     52.2   

  Cefuroxime                                  Intermediate   3                                               11.5                                             2          10.0   5      10.9

  Resistant                                   13             50.0                                            8                                                40.0       21     45.7   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Hospitalized patients with at least one overnight stay in hospital before diagnosis.

Outpatients and patients brought to emergency room.

Total number of episodes.

Number (percentage) of episodes in the specified category.

The two tested *H. influenzae* isolates were sensitive to all antibiotics except cefuroxime, for which they showed intermediate resistance (data not shown).

4.. Discussion {#s4}
==============

In this surveillance study, *S. pneumoniae* was confirmed in 7.5% of Saudi Arabian children \<5 years of age suspected of having IPD who were brought to one of the study hospitals. Although the confidence intervals overlapped, the point estimates of the incidence of IPD varied between 2.5/100,000 and 9.6/100,000 in children younger than 5 years of age in the different health areas included in the study, with the exception of 21.6 in Al-Baha City. Interestingly, apart from this one exception, the incidence in these areas was lower compared with 17.4/100,000 children reported by a previous study conducted in children younger than 5 years of age admitted to hospitals in Riyadh and Jeddah \[[@B3]\]. The proportion of IPD cases in children younger than 5 years old occurring in the less than 1 year age group (335/623; 53.6%) in the present study was similar to that observed in 1999--2003 (39/82; 47.6%) in Saudi Arabian children \[[@B3]\]. Nonetheless, the true burden of IPD, and thus the potential impact of a pneumococcal conjugate vaccine (PCV) is likely to be substantially greater than these numbers would suggest. A randomized clinical trial demonstrated that at least three times more clinically suspected IPD cases can be prevented by pneumococcal vaccination than microbiologically confirmed cases \[[@B17]\].

Pneumococcal serotypes 5, 23F, 6B, 1, and 14 were the most frequently identified serotypes in Saudi Arabian children with IPD in this study. This serotype distribution differs from that observed in 2000--2004, when serotype 14 was the most common serotype in Saudi Arabian children, followed by 23F, 6B, and 19F \[[@B6]\]. The serotype distribution in the present study, which enrolled children with clinical symptoms is, however, similar to that identified from isolates collected as routine surveillance in 2005--2010, when serotype 23F was the most common, followed by 6B, 5 and 1 \[[@B18]\]. In 2010, serotype 23F was the most prevalent in Saudi Arabia, followed by 19F, 19A, 6B, 7F, 5 and 1 \[[@B18]\]. Previously, serotypes 5 and 1 were infrequently identified (each in 1.4% of the isolates) \[[@B6]\], while in the present study, these serotypes were identified in 20% and 11% of the isolates, respectively. The differences in serotype distribution between the two studies are in line with previous observations \[[@B19],[@B20]\] that the seasonal peaks in IPD caused by serotypes 1 and 5 might occur following cyclical patterns every 3--4 years. In the present study, serotype 19A, which shows reduced susceptibility to antibiotics, was infrequently identified (1 single case representing 2.2% of the isolates), in line with previous findings in Saudi Arabia (2000--2004) \[[@B6]\]. However, in the post-PCV7 era, in 2009--2010, serotype 19A was considered to be responsible for 20% of IPD cases in the Western region of Saudi Arabia, possibly due to local antibiotic pretreatment practices, which could affect the serotypes isolated by blood culture \[[@B18]\]. The burden of IPD due to serotype 19A has been increasing in some countries around the world, especially in European and North American countries and in Australia \[[@B21],[@B22]\]. Finally, serotype 3 was not identified in young Saudi Arabian children with IPD, confirming the results of other studies showing that this serotype is not a common cause of IPD in this age group \[[@B22]\]. Although the aforementioned study \[[@B18]\] reported antibiotic resistance and serotype distribution, our study additionally calculated incidence based on the samples collected from patients with clinical symptoms.

Local epidemiological data are useful to evaluate the impact of pneumococcal vaccines on IPD. In the present study, the potential pneumococcal vaccine serotype coverage rates among Saudi Arabian children younger than 5 years of age were estimated to be 61% (28/46 isolates) for PCV7, and to be significantly higher for PHiD-CV (91%; 42/46 isolates) and PCV13 (93%; 43/46 isolates). However, these figures do not take into account potential cross-protection; evidence of cross-protection against serotype 6A has long existed for PCV7, and PHiD-CV is similarly immunogenic against that serotype; in addition, there is emerging evidence of cross-protection against serotype 19A for PHiD-CV \[[@B23]\].

In line with previous reports in Saudi Arabia, 63% of the *S. pneumoniae* isolates in this study showed multidrug resistance. The frequent occurrence of multidrug-resistant isolates may be partially explained by the high and inappropriate use of antibiotics in Saudi Arabia \[[@B6]--[@B14]\]. Of note, the proportion of isolates with decreased susceptibility to penicillin was higher in this study than in a previous study conducted in 2000--2004 (70% vs. 54%), using the same susceptibility criteria \[[@B6]\]. The proportion of fully resistant isolates was higher in our study compared with previous observations (39% vs. 12%), while that of isolates showing intermediate resistance to penicillin was lower (30% vs. 42%). It is important to note that we utilized the 2005 National Committee for Clinical Laboratory Standards susceptibility criteria in order to facilitate comparisons with the previous studies; applying the cutoffs associated with more recent Clinical and Laboratory Standards Institute 2014 criteria, which only affect interpretation of the penicillin results, would tend to decrease somewhat the proportion of nonmeningitis isolates considered fully resistant.

Nontypeable *H. influenzae* (NTHi) was identified in two episodes of suspected IPD. The 11-valent PCV using NTHi protein D as carrier, which was the precursor of PHiD-CV, has shown some efficacy against acute otitis media caused by NTHi \[[@B24]\]. However, additional studies are needed to determine whether PHiD-CV itself has such efficacy and whether efficacy would extend to invasive disease caused by NTHi. In this study, *N. meningitidis* was not responsible for any invasive disease episodes.

Limitations of this study include low culture positivity rate, a previously reported problem that could be mitigated by using molecular detection techniques \[[@B25]\]. False-negative cultures may result from previous antibiotic use, insufficient sample volume, or inadequate storage and transportation conditions \[[@B26]\]. The reported antibiotic use was high in enrolled children, especially outpatients, and possibly underestimated, since no urine antimicrobial tests were performed.

In conclusion, this multicenter prospective clinical surveillance study conducted between June 2007 and January 2009 showed that *S. pneumoniae* was the most commonly identified pathogen in Saudi Arabian children younger than 5 years of age with confirmed invasive disease. The most common pneumococcal serotypes were 5, 23F, 6B, 1, and 14, with antibiotic resistance being a major issue. Although this study was conducted largely in the pre-PCV era, these data remain relevant as vaccine-type IPD can continue to circulate and potentially cause disease even after several years of universal mass vaccination PCV programs \[[@B23]\]. Therefore, vaccination of Saudi Arabian children with expanded coverage conjugate pneumococcal vaccines, especially PHiD-CV and PCV13, would have a substantial impact to prevent IPD in this population.
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